This article is more than 5 years old. Information may no longer be current.

OptoLight receives CE mark for implantable mirror telescope

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HERTZLIA, Israel — OptoLight Vision Technology has received a CE mark for its Lipshitz Macular Implant, the company announced in a press release.

Indicated for magnifying the central visual field for patients with age-related macular degeneration and other degenerative retinal diseases, the implant is a modified IOL that integrates miniature mirrors to form a mirror telescope inside the eye. The device is the only implantable telescope that has the ability to magnify the central image without diminishing peripheral vision, the release said.

The CE approval will allow OptoLight to immediately begin marketing the implant in Europe and other markets outside of the United States.

"We are very pleased that a significant number of macular degeneration patients that until now had no medical treatment at all will be able to improve their vision by using our LMI technology," Isaac Lipshitz, MD, inventor and chief executive officer of OptoLight, said in the release. "The mirror telescope is a technological platform that will also enable us to help patients with other retinal disorders that have no effective medical treatment."